Tag Archives: Galmed

Insulet Hires New CEO; Galmed Sublingual Semaglutide; Vutrisiran ATTR-CM CHMP Opinion

Three cardiometabolic-related news items have been observed: Ashley McEvoy has been appointed as Insulet’s new CEO (view press release); Galmed announced an agreement with Entomus for sublingual semaglutide development (view press release); and CHMP adopted a positive opinion for the vutrisiran ATTR-CM indication (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Galmed MASH Open-Label Publication; Entera/OPKO GLP-1/GCG Pre-Clinical Update

Two cardiometabolic-related news items have been observed: Galmed published one-year open-label results from its Ph3 MASH study (view press release; view publication); and Entera Bio and OPKO Health provided updates on its preclinical oxyntomodulin asset in obesity (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Icodec up for CHMP Opinion; March CHMP Agenda; Galmed Granted MASH Combo Patent; Sequel’s twiist AID Receives 510(k) Clearance

Three cardiometabolic-related news items have been observed: The CHMP agenda for this month’s meeting (March 18-21) has been released and Novo Nordisk’s insulin icodec is up for an opinion (view CHMP agenda); Galmed announced it was granted an EU patent for the combination of aramchol and resmetirom for the treatment of MASH and liver fibrosis (view press release); and Sequel Med Tech announced it received 510(k) clearance for the twiist AID system (view press release). Additionally, FENIX has provided a correction to Novo’s new Rybelsus doses based on information from its Q3 2023 earnings press release. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here